CXCR2 inhibitors, such as SX-682, impair PMN-MDSC trafficking, which subsequently enhances the efficacy of T cell- and NK cell-based immunotherapies by allowing better immune cell infiltration and activity within the tumor [85,87]. The gene discussed is CXCR2; the disease is neoplasm.